Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial

Authors

Akira Uchiyama (ORCID: https://orcid.org/0000-0003-3814-2760)
Kazuyoshi Kon (ORCID: https://orcid.org/0000-0002-1127-2218)
Kenichi Ikejima (ORCID: https://orcid.org/0000-0002-2657-0840)
Kei Ishizuka (ORCID: https://orcid.org/0000-0001-9171-724X)
Reiko Yaginuma (ORCID: https://orcid.org/0009-0002-4873-3986)
Kyoko Fukuhara
Shuko Nojiri (ORCID: https://orcid.org/0000-0003-0422-8152)
Maki Morinaga (ORCID: https://orcid.org/0009-0008-3937-7338)
Hironao Okubo (ORCID: https://orcid.org/0000-0002-5995-199X)
Satoko Suzuki (ORCID: https://orcid.org/0009-0001-8166-2481)
Shunhei Yamashina
Hiroo Fukada (ORCID: https://orcid.org/0000-0003-3775-4474)